Extensive-stage small-cell lung cancer ( SCLC ) patients who progress after platinum-based chemotherapy are traditionally categorized as platinum sensitive ( progression @ days from last platinum dose ) or refractory ( progression < @ days ) , a practice arising from seminal observations of worse survival in refractory patients .